找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Biologic Therapy for Psoriasis; Cutting Edge Treatme Nicholas Brownstone,Tina Bhutani,Wilson Liao Book 2022 The Editor(s) (if applicable) a

[復(fù)制鏈接]
樓主: Disaster
21#
發(fā)表于 2025-3-25 06:06:56 | 只看該作者
https://doi.org/10.1007/978-3-642-36999-5 IL-17 antagonists have also shown sustained treatment responses and a quick onset of action. The high response rate seen in IL-17 inhibitors in the treatment of moderate-to-severe psoriasis underscores the importance of the IL-23/Th17 pathway in the pathogenesis of psoriasis.
22#
發(fā)表于 2025-3-25 11:02:14 | 只看該作者
2523-8884 h.Examines the 11 FDA approved biologic agents currently on .Biologic therapy is a treatment that strives to?modulate?a patient‘s immune system to fight a given disease. In psoriasis, a skin disorder that?is?partly caused by a dysregulated immune system resulting in?well-demarcated red areas of the
23#
發(fā)表于 2025-3-25 15:09:20 | 只看該作者
Kinderallergologie in Klinik und Praxisused in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.
24#
發(fā)表于 2025-3-25 16:04:44 | 只看該作者
Genetik, Epidemiologie und Pr?vention context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.
25#
發(fā)表于 2025-3-25 23:04:30 | 只看該作者
Kinderallergologie in Klinik und Praxiso-severe disease. Recent data have shown that biologics offer a safe and effective option for children. Currently, etanercept, ustekinumab, ixekizumab, and secukinumab are approved by the Food and Drug Administration for treatment in children. Approach to the use of biologics for pediatric psoriasis is detailed in this chapter.
26#
發(fā)表于 2025-3-26 02:57:37 | 只看該作者
27#
發(fā)表于 2025-3-26 06:18:28 | 只看該作者
Introduction to Biologic Therapy for Psoriasis,used in psoriasis is presented. Finally, outcome measures in psoriasis clinical trials are also introduced with the goal of making it easier to interpret results from research and development of psoriasis biologic agents.
28#
發(fā)表于 2025-3-26 09:15:40 | 只看該作者
TNF-Alpha Class of Biologic Agents in Psoriatic Disease, context of association between increased efficacy, infection, and malignancy. Delineation of the beneficial and deleterious effects of these medications fosters greater precision in appropriate regimen selection.
29#
發(fā)表于 2025-3-26 13:07:54 | 只看該作者
30#
發(fā)表于 2025-3-26 19:24:03 | 只看該作者
Special Site Psoriasis,r in patients’ quality of life, localization of psoriasis to specialized areas of the body can also cause stigmatization and physical and psychosocial burden. In this chapter, we will review treatment options for special sites of psoriasis, focusing on the efficacy and safety of biologic agents.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 18:06
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
阿合奇县| 宽城| 达州市| 靖远县| 广水市| 商南县| 醴陵市| 南雄市| 陆良县| 县级市| 钟祥市| 康平县| 天津市| 江达县| 晋宁县| 湘乡市| 绥德县| 梓潼县| 永康市| 平潭县| 林甸县| 从江县| 东海县| 白玉县| 五寨县| 洞口县| 岳阳县| 陆川县| 怀柔区| 光泽县| 巧家县| 扎赉特旗| 新田县| 双桥区| 彰化县| 石台县| 盐亭县| 平南县| 胶州市| 揭西县| 马公市|